Payment overview · 2025
General Payments
$890.83
32 reported records · 11 companies
Healthcare provider profile · identity verified
James E Gleason, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIVERDALE, GA · NPI 1780649368
Verified facts
What the public records show
CMS Open Payments records show James E Gleason, MD received $890.83 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.05 | 25.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.32 | 22.8% | 9 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $148.63 | 16.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.22 | 13.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.02 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.93 | 2.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $24.79 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.92 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.74 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.49 | 2.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $16.72 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $890.83 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $173.18 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.75 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.27 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $121.71 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.05 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.85 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 351 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 27 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
351 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
351 | 78 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
259 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 524 | 158 |
| Montelukast Sodium | Montelukast Sodium | 484 | 173 |
| Jardiance | Empagliflozin | 351 | 78 |
| Losartan Potassium | Losartan Potassium | 345 | 89 |
| Metformin Hcl Er | Metformin Hcl | 265 | 80 |
| Mounjaro | Tirzepatide | 259 | 45 |
| Alprazolam | Alprazolam | 238 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 69 |
| Spironolactone | Spironolactone | 200 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 52 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 177 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 51 |
| Famotidine | Famotidine | 157 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 156 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 41 |
| Ozempic | Semaglutide | 143 | 25 |
| Meloxicam | Meloxicam | 136 | 40 |
| Lisinopril | Lisinopril | 133 | 43 |
| Tramadol Hcl | Tramadol Hcl | 127 | 22 |
| Potassium Chloride | Potassium Chloride | 119 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 17 |
| Simvastatin | Simvastatin | 117 | 38 |
| Furosemide | Furosemide | 111 | 34 |
| Gabapentin | Gabapentin | 111 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 33 |
| Farxiga | Dapagliflozin Propanediol | 103 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 31 |
| Pregabalin | Pregabalin | 101 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 27 |
| Carvedilol | Carvedilol | 96 | 34 |
| Lorazepam | Lorazepam | 91 | 18 |
| Omeprazole | Omeprazole | 89 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 27 |
| Fluconazole | Fluconazole | 84 | 39 |
| Clonidine Hcl | Clonidine Hcl | 83 | 21 |
| Nifedipine Er | Nifedipine | 78 | 23 |
| Prednisone | Prednisone | 77 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 18 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 19 |
| Ondansetron Odt | Ondansetron | 66 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 23 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Irbesartan | Irbesartan | 62 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Linzess | Linaclotide | 58 | 17 |
| Torsemide | Torsemide | 56 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 16 |
| Naproxen | Naproxen | 51 | 11 |
| Chlorthalidone | Chlorthalidone | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Glimepiride | Glimepiride | 48 | 15 |
| Methocarbamol | Methocarbamol | 48 | 15 |
| Mupirocin | Mupirocin | 47 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Levofloxacin | Levofloxacin | 46 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 18 |
| Nystatin | Nystatin | 45 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 13 |
| Eliquis | Apixaban | 40 | 11 |
| Metformin Hcl | Metformin Hcl | 40 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Allopurinol | Allopurinol | 38 | 16 |
| Ibuprofen | Ibuprofen | 38 | 21 |
| Ciclopirox | Ciclopirox | 36 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Klor-Con M20 | Potassium Chloride | 35 | 12 |
| Celecoxib | Celecoxib | 34 | 12 |
| Sucralfate | Sucralfate | 34 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Colchicine | Colchicine | 28 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Belsomra | Suvorexant | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 18 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $890.83 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CABENUVA, DOVATO, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, NEFFY, Ozempic, QULIPTA, Quviviq, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error